- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05380284
Senior Driving Simulation Training for Subjective Cognitive Decline and Mild Cognitive Impairment (SDST)
May 29, 2023 updated by: Huie-Ling Chiu, Taipei Medical University
Evaluation of Senior Driving Simulation Training on Executive Function, Cognitive Promotion and EEG in Subjective Cognitive Decline and Mild Cognitive Impairment
This study aims to establish the Senior Driving Simulation Training (SDST) for Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI), and explore the effectiveness of Senior Driving Simulation Training (SDST) on the executive function, cognitive function and EEG.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Driving behavior is a high cognitively demanding task, and whether the Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) can continue to drive is an important issue.
This study will develop the Taiwan version of innovative, immediate feedback and environmentally safe Senior Driving Simulation Training (SDST).
This study aims to establish the Senior Driving Simulation Training (SDST) for Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI), and explore the effectiveness of Senior Driving Simulation Training (SDST) on the executive function, cognitive function and EEG.
The investigators intend to conduct a single-blind randomized controlled trial using a two-arm parallel-group design.
Participants will be randomized by the permuted block randomization, block size of 4, into an experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) or a control group (Waiting list).
The investigators plan to blind the therapists and outcome assessors to maintain the blinding methods' quality.
The primary outcome indicators are mental set-shifting, working memory, and inhibition.
The secondary outcome indicators are cognitive function and EEG.
The investigators also evaluate visual awareness and simulator sickness.
The short-term (immediate post-test) and the long-term (3, 6, and 12 months) effectiveness of the intervention on individual outcome measures will be analyzed by the generalized estimating equation.
The investigators also plan to use the secondary data analysis methods to investigate the relationship between objective indicators of a driving simulator, executive function, cognitive function, EEG, visual awareness, and simulator sickness.
Furthermore, the investigators will analyze the trend of EEG while the participants conducting the training, and complete the psychometric properties of the Chinese version of the Cognitive Change Index (C-CCI).
This will be the first senior driving simulation training (SDST) for Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) in Taiwan.
Results of the current study will provide valuable information on driving safety decisions and apply to promote the advanced driving policies.
Study Type
Interventional
Enrollment (Actual)
90
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 110
- Taipei Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Subjective cognitive decline( AD-8 scale ≥1 point).
- Mild cognitive impairment (AD-8 scale ≥ 2 points), and MMSE> 24 points, can maintain personal daily activity function.
- Can communicate in Chinese or Taiwanese.
- At least 60 years of age.
- Those with a car driving license.
- No physical impairment.
- In addition to the above conditions, participants must be voluntary and signed informed consent.
Exclusion Criteria:
- Dementia, diagnosed by a physician and in compliance with ICD-10.
- Significant mental illness or communication impairment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental Group
Senior Driving Simulation Training
|
The experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) .
|
|
Other: Control Group
Waiting-list
|
The control group is waiting list control.
They will also receive the (Senior Driving Simulation Training) after all research is done.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mental set shifting, measured by Wisconsin Card Sorting Test
Time Frame: immediate post-test
|
Mental set shifting is one of the sub-categories of executive function
|
immediate post-test
|
|
Change from Baseline Mental set shifting, measured by Wisconsin Card Sorting Test at 3 months
Time Frame: 3 months follow-up
|
Mental set shifting is one of the sub-categories of executive function
|
3 months follow-up
|
|
Working memory, measured by Digit span test
Time Frame: immediate post-test
|
Working memory is one of the sub-categories of executive function
|
immediate post-test
|
|
Change from Baseline Working memory, measured by Digit span test at 3 months
Time Frame: 3 months follow-up
|
Working memory is one of the sub-categories of executive function
|
3 months follow-up
|
|
Inhibition, measured by the Stroop Color and Word Test
Time Frame: immediate post-test
|
Inhibition is one of the sub-categories of executive function
|
immediate post-test
|
|
Change from Baseline Inhibition, measured by the Stroop Color and Word Test at 3 months
Time Frame: 3 months follow-up
|
Inhibition is one of the sub-categories of executive function
|
3 months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive function measured by Montreal Cognitive Assessment
Time Frame: immediate post-test
|
Cognitive function measured by Montreal Cognitive Assessment
|
immediate post-test
|
|
Cognitive function measured by Cognitive Change Index(C-CCI)
Time Frame: immediate post-test
|
Cognitive function measured by Cognitive Change Index(C-CCI)
|
immediate post-test
|
|
Change from Baseline cognitive function by Montreal Cognitive Assessment at 3 months
Time Frame: 3 months follow-up
|
Change from Baseline cognitive function by Montreal Cognitive Assessment at 3 months
|
3 months follow-up
|
|
Change from Baseline cognitive function by Cognitive Change Index(C-CCI)at 3 months
Time Frame: 3 months follow-up
|
Change from Baseline cognitive function by Cognitive Change Index(C-CCI)at 3 months
|
3 months follow-up
|
|
EEG
Time Frame: immediate post-test
|
EEG power in delta, theta, alpha, and beta band
|
immediate post-test
|
|
Change from Baseline EEG at 3 months
Time Frame: 3 months follow-up
|
EEG power in delta, theta, alpha, and beta band
|
3 months follow-up
|
|
Visual awareness measured by CANTAB
Time Frame: immediate post-test
|
Visual awareness measured by CANTAB
|
immediate post-test
|
|
Visual awareness measured by trail making test
Time Frame: immediate post-test
|
Visual awareness measured by trail making test
|
immediate post-test
|
|
Change from Baseline visual awareness by CANTAB at 3 months
Time Frame: 3 months follow-up
|
Visual awareness measured by CANTAB
|
3 months follow-up
|
|
Change from Baseline visual awareness by trail making test at 3 months
Time Frame: 3 months follow-up
|
Change from Baseline visual awareness by trail making test at 3 months
|
3 months follow-up
|
|
simulator sickness
Time Frame: immediate post-test
|
Simulator Sickness Questionnaire (SSQ).
The 16-item SSQ will be used to assess participants' sickness levels.
This is the 4-point Likert scale (0 - "None" to 3 - "Severe"), and the higher total score reflects more severe sickness.
|
immediate post-test
|
|
Usability
Time Frame: immediate post-test
|
The System Usability Scale (SUS) will be used to access the usability, this scale consists of 10 items, and the higher total score reflects better usability.
|
immediate post-test
|
|
Acceptance
Time Frame: immediate post-test
|
The Technology Acceptance for Older Adults Scale will be used to access the acceptance, this scale consists of 17 items, and the higher total score reflects better acceptance.
|
immediate post-test
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Huei-Ling Chiu, Taipei Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2022
Primary Completion (Actual)
January 1, 2023
Study Completion (Actual)
May 28, 2023
Study Registration Dates
First Submitted
April 30, 2022
First Submitted That Met QC Criteria
May 14, 2022
First Posted (Actual)
May 18, 2022
Study Record Updates
Last Update Posted (Actual)
June 1, 2023
Last Update Submitted That Met QC Criteria
May 29, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N202002083
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.